Legend Biotech reported CARVYKTI® net trade sales of $963 million for full year 2024, with over 5,000 patients treated to date, positioning the CAR-T therapy as a market leader in multiple myeloma treatment.
DelveInsight's comprehensive analysis reveals over 200 companies actively developing 220+ pipeline therapies for gastric cancer treatment, indicating significant industry investment in addressing this disease.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.